Management of GI Issues with Anti-Inflammatory Medication

Risk Stratification and Treatment Algorithm

For patients with GI issues requiring anti-inflammatory therapy, the American Gastroenterological Association recommends using a COX-2 selective inhibitor or a traditional NSAID plus proton pump inhibitor if they have prior GI complications, while COX-2 inhibitors alone are appropriate for those on aspirin without prior GI events 1, 2, 3
The selection algorithm is based on three critical factors that determine GI risk, including previous GI event, age, and concomitant aspirin, steroids, or anticoagulant use, with previous GI event being the strongest predictor of increased risk 1, 4
Patients with previous GI events should be treated with COX-2 selective inhibitor or traditional NSAID plus PPI, with both strategies rated as "appropriate" with equivalent gastroprotection 1, 2, 3
For patients on aspirin, the first choice is NSAID plus PPI or COX-2 inhibitor plus PPI, with the combination of COX-2 plus PPI providing superior protection when aspirin is co-administered 1, 2, 3, 5

Traditional NSAID alone should not be used in patients with previous GI events, as it is rated "inappropriate" 1, 2, 3
COX-2 inhibitor alone should not be used in patients with previous GI events who are not on aspirin 1, 2
PPI co-therapy reduces upper GI complications by 75-85% in high-risk NSAID users, but does not protect against lower GI complications from NSAIDs 5
The American Heart Association recommends considering cardiovascular risk when using COX-2 inhibitors, particularly in elderly patients 1

For patients requiring analgesia without anti-inflammatory effects, acetaminophen ≤4g/day is the safest first-line option, with doses above 3,250mg/day showing dose-dependent GI events approaching those of high-dose NSAIDs 4
H. pylori testing should be considered if status is unknown, as infection increases NSAID-related GI complications 2-4 fold 5
The lowest effective dose of NSAID should be used for the shortest duration necessary, with monitoring for signs of GI ulceration/bleeding even in patients on gastroprotective therapy 4, 6